SARS-CoV-2 RNA polymerase as target for antiviral therapy
SARS-CoV-2 RNA polymerase as target for antiviral therapy
复制标题
DOI：
10.1186/s12967-020-02355-3
复制
发表时间：
2020-05-05
影响因子：
7.4
通讯作者：
Buonaguro, Franco M.
中科院分区：
文献类型：
--
作者：
Buonaguro, Luigi;Tagliamonte, Maria;Buonaguro, Franco M.
2019年12月，在中国武汉的几例急性呼吸道综合征病例中发现了一种名为SARS-CoV-2的新型人类冠状病毒。2020年3月11日，世卫组织宣布SARS-CoV-2感染为大流行，基于169个国家的参与。针对SARS-CoV-2的特效药显然还没有。目前，最初针对其他病毒或寄生虫开发的药物目前正在基于经验数据进行临床试验。在寻求有效的抗病毒药物时，RNA病毒最特异的靶标是RNA依赖性RNA聚合酶（RdRp），其在正义和反义RNA病毒之间显示出显著差异。准确评估不同病毒的RdRps可能会指导新药的开发或重新定位已批准的抗病毒药物作为SARS-CoV-2的治疗。这可以加速SARS-CoV-2大流行的遏制，并有希望加速未来由其他新出现的人畜共患RNA病毒引起的大流行的遏制。
A new human coronavirus named SARS-CoV-2 was identified in several cases of acute respiratory syndrome in Wuhan, China in December 2019. On March 11 2020, WHO declared the SARS-CoV-2 infection to be a pandemic, based on the involvement of 169 nations. Specific drugs for SARS-CoV-2 are obviously not available. Currently, drugs originally developed for other viruses or parasites are currently in clinical trials based on empiric data. In the quest of an effective antiviral drug, the most specific target for an RNA virus is the RNA-dependent RNA-polymerase (RdRp) which shows significant differences between positive-sense and negative-sense RNA viruses. An accurate evaluation of RdRps from different viruses may guide the development of new drugs or the repositioning of already approved antiviral drugs as treatment of SARS-CoV-2. This can accelerate the containment of the SARS-CoV-2 pandemic and, hopefully, of future pandemics due to other emerging zoonotic RNA viruses.